WALTHAM, Mass.--(BUSINESS WIRE)--TScan Therapeutics, a biopharmaceutical company focused on the development of T cell receptor (TCR) therapies which reprogram a patient’s own T cells to recognize ...

TSC-101 infusions were generally well-tolerated, safety was consistent with Cohort A, and observed adverse events were consistent with post-HCT adverse events.

WALTHAM, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX) ("TScan" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of T cell ...

From what we can see, insiders were net buyers in TScan Therapeutics, Inc.'s (NASDAQ:TCRX ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. While ...

Ratings for TScan Therapeutics (NASDAQ:TCRX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...

WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T ...

Collaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan’s lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to ...

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...

Amgen Inc AMGN and TScan Therapeutics Inc TCRX announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in ...

WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...

TScan Therapeutics Inc. (NASDAQ:TCRX), a biotechnology company specializing in T-cell receptor (TCR) engineered T cell therapies, stands at a critical juncture in its development pipeline. With key ...

Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2™) planned for the second quarter of ...